Virend
Virend Uses, Dosage, Side Effects, Food Interaction and all others data.
Virend, previously known as the investigational drug SP-303, is a novel proanthocyanidin purified from the bark latex of the Amazonian Croton tree Croton lechleri. It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.
Virend is an inhibitor of secretory diarrhea via inhibition of the CFTR chloride transporter. Virend is not an antimicrobial, and therefore does not drive the emergence of resistance; it does not inhibit motility, and therefore does not cause constipation or rebound diarrhea; and it is not systemically absorbed, reducing the potential for adverse drug interactions and toxicity.
| Trade Name | Virend |
| Availability | Prescription only |
| Generic | Crofelemer |
| Crofelemer Other Names | Crofelemer |
| Related Drugs | loperamide, Lomotil, Imodium, neomycin, Pepto-Bismol, bismuth subsalicylate |
| Type | |
| Protein binding | Since crofelemer is not significantly absorbed, protein binding was not quantified. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Virend is an antidiarrheal agent used for the symptomatic relief of drug-induced non-infectious diarrhea in adult patients with HIV/AIDS receiving antiretroviral therapy.
For the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.
Virend is also used to associated treatment for these conditions: Non-infectious Diarrhea
How Virend works
Virend is an inhibitor of the cystic fibrosis transmembrane regulator chloride channel (CFTR), as evidenced by its activity on cell cultures, single cell patch clamps, single CFTR channels, and elaboration of mouse intestinal fluid secretion. Virend also inhibits calcium activated chloride channels (CaCC), which in combination with CFTR, are expressed on the luminal side of intestinal cells. Virend inhibition of both of these channels prevents water loss from diarrhea by inhibiting chloride secretion.
Toxicity
The most common adverse effects are cough, flatulence, upper respiratory tract infection, bronchitis, and increased bilirubin.
Food Interaction
- Take with or without food.
Volume of Distribution
Since crofelemer is not significantly absorbed, volume of distribution was not quantified.
Elimination Route
The absorption of crofelemer is minimal and crofelemer concentrations in plasma are below the level of quantitation (50 ng/mL).
Half Life
Since crofelemer is not significantly absorbed, the half life was not determined.
Clearance
Since crofelemer is not significantly absorbed, clearance was not determined.
Elimination Route
Since crofelemer is not significantly absorbed, the route of elimination has not been identified.
Innovators Monograph
You find simplified version here Virend
